Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 2 Medical therapies used prior to start of LDN and concomitantly with LDN

From: Low dose Naltrexone for induction of remission in inflammatory bowel disease patients

 

UC, 19

CD, 28

Combined, 47

Prior and concomitant therapies

 Therapies prior to LDN, N (%)

  5-ASA

17 (89%)

14 (50%)

31 (66%)

  Steroids

19 (100%)

28 (100%)

47 (100%)

  Immunosuppressives

18 (95%)

27 (96%)

45 (96%)

  Anti-TNF

16 (84%)

25 (89%)

41 (87%)

  Other

5 (26%)

2 (7%)

8 (15%)

 Concomitant therapies at start of LDN, N (%)

  5-ASA

7 (37%)

3 (11%)

10 (21%)

  Steroids

6 (32%)

18 (64%)

24 (51%)

  Immunosuppressives

8 (42%)

9 (32%)

17 (36%)

  Anti-TNF

5 (26%)

3 (11%)

8 (17%)

  Other

1 (5%)

2 (7%)

3 (6%)

  None

4 (21%)

7 (25%)

11 (23%)

  1. Steroids refer to any form of corticosteroids. Immunosuppressives refer to thiopurines or methotrexate. Other refers to tacrolimus, cyclosporine, thioguanine or blinded trial drugs
  2. anti-TNF anti-tumor necrosis factor, CD Crohn’s disease, LDN low dose Naltrexone, UC ulcerative colitis
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us